Last edition
News about "GNX1021"
GlycoNex Doses First Patient in Phase 1 Trial of GNX1021
GlycoNex dosed the first patient in its phase 1 trial of GNX1021, advancing its glycan-directed Antibody Drug Conjugate (ADC) while exploring global licensing and co-development deals.
GNX1021 | 03/08/2026 | By News Bureau
GlycoNex Secures PMDA Nod for First-in-Human Trial of Cancer Drug GNX1021
Japan’s Pharmaceuticals and Medical Devices Agency approves Phase I clinical trial of GlycoNex’s novel antibody-drug conjugate targeting gastrointestinal cancers.
GNX1021 | 16/04/2026 | By News Bureau | 309
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy